Ca2+release from sarcoplasmic reticulum is slowed down in heart failure  by Yamamoto, T. et al.
JACC I':ehmaQ 19t)X ,'ql~;TI, tA(~T~ l',,,,=c'l ~gA 
Conctuston: Low dose ol Md substl~n0ally improved LV relaxabon in as- 
soctahcn wtth stimulation of Ca' ~TPase activity in sarceptasm~c rot=culum 
~ - ~  Tota l  Body  En(lothclln-1 Kinetics in Normal  
Sub j . : re  end Heart Fai lure Pat ients:  A New 
Rad lo t rac~r  Approach  
A,S, Pandey, J,J Thtes~en, D J  Slowan, JD Parker Umvem~ty atToront~ 
Toronto, O.fantx C~na(/a 
Endothelin- 1 lET-t) is elevated in CHF, althoqgh lfs kmettcs are po0dy under. 
stood in humans, We descnbe a technique ot ~l-!abelled ET.t ('~l.ET~l) 
ifl~StOn tO d~femline total ~ ET-t kinol~cs. 
&l/efhOo~.~'lesu~: 5= nora',SiS and 5 CHF patients were sttMted. Over 5 
minutes, 50 m~'ocune~ 0f ~ l .E ' r . t  wore refused. Hemodynamics #lnd blood 
samples_ wel~ Obta i~ 31 limes over 240 minutes, Afler Cla col~lmn e~lrac. 
lion, plasma was counted m a gamma counter. ET-1 plasma levels were 
measorod using an enzyme Immunoassay lechn!¢l~,l~. Ki~,~,tics Of ~I.ET.1 
clearance were modelled thmu0h standard computer modelhng ~ystems 
Basehne O~cutating ET-! levels were elevated m the CHF palients [282 
106 pg.,~! vs 097 ± 043, P ~ 0.05) There were no changes in homo- 
dynam~,s Or Ctrcutatmg ET-I levels w~th "%I-ET-1 infusmn =n e0her group 
The kinettCS 01 ET-1 clearance were best descnbecl by a three compartment 
model wlfh a prolonged terminal half life (455 ¢ 59 minutes, normals; 20689 
~. 2017'2, CHF). The steady state volume et d~stnbubon was large but atg- 
nifcantly smaller in CHF patients (34.9 ~, 99 L~g vs 23.7 ± 6.4 P - 0.05) 
The elearanoe rate at ET-t from plasma was slower m CHF patmnts (0066 
0.0088 I.Jkg~mm vs 0.036 ~: 0.012, P = 0.05) 
Cor¢tusK~ns: Th~s stuo'y desc.bes a three compartment pharmacok,not~c 
profile for ET-1. Its terminal hall life and plasma volume at d~stnbuhoe are 
sign~ficantiy lan3er than ~ev~ous reports. The pharmacekinet~c profile of CHF 
pahents ~s altered and may explain ~ts elevatnd ctrCulating levels. 
~ l r h e  Neuronal  NorelPlnephrine Transpor ter  in 
IE=perimental Heart Fai lure A f te r  Supracoronary  
Aortic Banding in the  Rat  
M Haass, J. Backs, M.M. Borst. S.H Gerber. P. Szala=. L Khmaschewskl ~ ,
R.H. Strasser. Departments of Cardiology. Germany. 'Anatomy. Unn~ers~ty 
ot He,de/berg. Germany 
Background: Cardiac net secretion el norepmepnnne (NE) =s increased m 
congesbve head failure. To further elumdate the role of the neuronal nore- 
pmephnne transporter (NET, uptake~ )expenments were pefforme~ m rats 
w~th supracoronary aod=c banchng. 
Methods and ResultS: Compared to sham operated control rats. rats wtth 
aortic banding were characterized by myocardial hypertrophy (heart weight 
1 77 ± 0.08 vs. 122 ~ 0.02 g). pulmonary congest=on (7.24 .- 0 38 vs 409 : 
0.16 g). and increased plasma NE (4 4 : 0.8 vs. 3.0 = 06 nmol;0 In ~solarecl 
pedused nearts funobonal ,mpa=rment el NET was md~cated by It) the uptake 
of [3H]-NE being reduced (20 ± 1 vs. 30 z 2%) and (11) pharmacelog=cal 
blockade o1 NET wtlh aesipram~ne (DMI. 300 nmot~tl leading to a d~rmntshed 
increase in endogenous NE release evoked by electncal field stlmul0hon (4 
HZ. 1 mini ($2/Sl 1.2 ± 0.2 vs. 1 7 ~ 01: St: control: St; alter DMI} in 
:: 6, p < 0.05 each). RT-PCR was used to study NET g¢~e expression 
In situ hybndlzatton v~th the DIGJabeled PCR product revealed a dense 
hybndizaticn in the penkarya cf tyrosme hydroxylase pos=tr~e cell bodies 
w0hin the left stellate ganghon but neither in efferent car~ac nerves nor the 
head. NET mRNA concentratrons of the left stellate ganglion were quantified 
by competihve RT-PCR. as was 18S rRNA to control tar intact RNA. However. 
there was no significant difference between aodic banded and sham operated 
rats (1.65 ± 0.11 vs. 1.81 ~ 0.07 NET mRNA]18S rRNA ~ 10 ~, n = 6) 
Concluston: Cardiac NE uptake by the NET is imps=red in aortic banded 
rats with head failure despde unaltered NET gene express=on 
~ Endothe l in  Receptor  Improves  B lockade  Left 
Ventr icu lar  Pressure-Volume Relat ionships  
Without Altering the Hypertrophic Response 
During Congest ive  Heart Fa i lure in Rats 
E. Oie ~ , R, Bjomerhelm ~, H.K. Grogaard ~ . O,A. Smiseth ~. H. Attramadal ~ .
~ MSD - CVRC, Nonyay, ~ Med. Dept. B. The National Hospital University at 
Oslo. Oslo. Nonvay 
Background: The role played by endothelin-1 (ET-1) in the progression ot 
congestive heart failure (CHF) remains unknown. We investigated the effects 
of ET receptor blockade on cardiac dimensions and dynamics, and on gone 
expression markers of hypertrophy during CHF 
Methods: Alter ligation of the left coronary artery, rats were randomized 
to oral treatment with a non-selective ET receptor antagonist (Bosentan, 100 
mg/kg/day, n = 11) or saline (n = 13) for 15 days starting 24 hours after 
the tnducbon ot mycx:ardtal *ntarc1~on T0n she ,-Operated fats rece~., ' ,,o 
treatment 
Results Right venlncular wl/t:X:K~ wl tetras were incroaseo Dy 65% =~ 
both the CHF groups (p ~ 005) E~.hoca~mgrapny feveatecl an ,ncteas~ ~n 
taft ventncut~f end-O~a~tohc d~mens~orr~ (LV EDD) tram 57 • 0 1 in ~ s~'n  
group to 8,7 • 0.2 mm In the CHF-sahne group, wh*l~ tr~.'ffmnal ~
(FS) was decreased from 3~ ~ 2 to 12 z 1% (p ,: 0.05) Inteeventmn w~h 
bosentan Caused 35% red~tt0n in LV ddatatmn (LVEDD 7.6 ~ 03 ram) 
an~ 49%, increase ,n FS (to 18 z 1%) compared to vel'~cte (p ~ 005) 
Bosentan also roducect LV enc~a~ttohc PreSsgra fro~ 23 z i to 20 • 2 
mmHg and LV systole pressure from 107 ~ 3 Io 99 ~ 2 mmHQ (p ~ 0.051 
Express~on o! prepreET.1. ANP, BNP, p.MHC ar~ fikeletal ~.actin mRNAs 
were all marke~y a~d ~ignd'~csnthl mCre~od In nenq,~chem~c myoca~c~-rn ,~-~ 
CHF No drfferer~es were obsewed between the CHF gre~.  
Conclusion Intervention w=lh Bosentan dramatically improves LV pres~ 
-,ure-volume relationships and cardiac dynamics wnhout altenng the hype~, 
trophie response dunng CHF in rats 
~ ~3~ w.at le the sour~= of ,ncm~ Mwc=.d~,l ~.mo. 
Necrosis Factor-alpha In Heart Fai lure? 
GW Mo~, R Ou, A. AIb~rnaz, G Na,k, P LJu Unlversrty of Toronfc~ 
Toronto, Onlarlo, Canada 
Background Tumor necrosis factor-alpha (TNF-a) Is a pleolrep=c premftam- 
matory cytokme and plasma TNF-a level appears to cater prognosis m pa- 
tlents wnb heart fadum (CHF) However, there =s debate regar~ng the soume 
at the increased TNF-a. Some investigators argue Ihet TNF-a is produced 
by =mmune activatmn at end stage CHF. We therefore studmd TNF.a ~n a 
clog model at pacmg-~nduced CHF in which there ~s IJMle tissue tnMammah~ 
re~panse. 
Mettm~s. Six dogs were nght ventncular-paced at 250 beats~rmn mr 3 
weeks to severe CHF Senal plasma levels (mean ~ SE) of TNF-a (by 
ELISA, pcjJml} and noropmephnne (NE. by HPLC, pg/ml) are shown 
• p 0 05 versus t~aselme 
Baseline Week 1 Week 2 Week 3 
TNF-a B : 4 79 ± 27" 89 z 25' 247 ~ 98" 
NE 23? t 34 391 ~ 62 445 t 74" 644 ~ ~64" 
Results: EvoMng CHF =.~ accompanied by a progresstve increase cn 
plasma TNF-a and NE Immunohistochemical studies of the LV of the paced 
ct~gs revealed intense staining for TNF-a m the myocytes, endothehal ana 
smooth muscle layers, but not m the tibreblasts. These change.~ were not 
observed in conlrel normal d~ Staining el the spleens from the paced 
dogs were s~mffar to lhe controls 
Conclusion: Increased plasma and myocardial TNF-a m a model of CHF 
with ht~le immune pathegenes=s uggests a pnmary product=on of TNF-a ~n 
the heart without a reclu~rement of immune activation. 
~ C a  ~* From Reticulum Is Release Sarcoplasmic 
Slowed Down In Heart  Failure 
T Yamamolo. M. Yano, M Kohno. K One 1". Hisaoka, T. Tanlgawa, 
T OhkuSa. f',~. Malsuzak~. Yamaguchi UmverSrfy, Ube, Japan 
Background." In heart tadure, little informatmn is available as to the Ca ~" 
release function of SR which plays a maior role on cardiac contractility. 
Method: The SR vesicles were isolated from dog LV muscles (normal 
[N]. n = 7: pacing induced heart fadure [HF], n = 6). The lime course of 
SR Ca 2" release was car :muously monitored by a stopped-flow apparatus 
using arsen3zol[I as Ca;" indicator, and [3H]ryanoclino (Ry) binding assay 
was done using flltratmn method. 
Resu/t: As compared ~-,tth N. LV end-diastolic pressure was elevaled by 
380 • 91% (p . 001). The peak + dP/dt was decreased by 24 = 13% 
(p = 0.01) wh~le hme co, natant at LV pressure d~,.,ay dunng isovolum~c 
relaxation was increased by 19 : 8% (p - 0.01), indicating HF The amount 
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nermal 
? 
290A ABSTRACTS-- Po~tcr JACC Fohmar), 1998 
end the initial rote of polylysino (PL:a specific release triggor)-inducod Ce "~" 
releeso wore both decreased In N compared with HF (Fig), However, the PL 
concentration ([PL]} dependency of the initial rate sl~lftod toward lower [PL] 
in HF than in N ((PL] el I~alt mnxtmum stimulation ,~ 0,11 t~M ve 0,38 aM), 
The % ratio 01 Ce ~* roloesed to Ca '~' sequestered we8 lower in HF (10,2 
13,5",) than In N (31,6 :L 15,0%) (p ~ 0,05), The [3H]Ry binding assay 
revealed lower Bronx (pmol/mg) In HF than N (0,73 t 0,24 ve 3.11 t 1,47. p 
-~ 0,01), but no difference In Kd (aM) (0,98 ~; 0.31 vs 1.05 ~t~ 0,29. n,s.). 
Concl~.~ton: In pactng.lnducod Ito,~rt failure, the function of SR Ca"  
release channel Is disturbed, which may result In t~ leakiness of SR mombrnne 
and a slowed Inlracollular Ca ~* transient, 
'~  and Protein In Skeletal Apoptosls pS3 Expression 
Myocytos of Patients With Chronic Heart Failure: 
Implications for Exercise Intolerance 
V, Adams, R, Hambrocl~t, J Yu, S, M~blu~,Winkler, E, Fiohn, A, Linko, 
C, Wetgl, L, Htlbrich, G, Scltulor, Hemt.Cenfer Letp~rg, University Leipzig, 
Leipzig, Germany 
Metabollo nfld ntrgctural altemtlon~ o! skeletal mueclo (SMI limit the exer- 
cise t01erence tn patients (pie) with chronic I~eart failure (CHF) Recently, 
apopto~la could be detected in eaKliac mvooytes, of pt~ with CHF, suggesting 
tl~at apoptosi~ contrib~,tto  tt~o rodt4oed eontta¢~tile ~omo and, therefore, 1o 
progression at the underlying disease, The present ekldy was undertaken Io 
invoMig~to the Occurrence of npaptoaia tn ,SM el pts with CHF and ;to rolatron 
to p53 prololn expression 
Twenty,nine pts wlt!~ CHF and ~ healthy controls underwent aymptomllro, 
lied bicycle orgo~pirom~tn/an well as pemolaneatm needle biopsy (m,vastus 
latoralis), Apolosls was vlntlalltod by the deoxynucloolidyl transferees as- 
say and revealed the pm~onco of lrttgmonmntod DNA in 20 pts (69%) and 
in none of the I~oalthy controls. Pts wqh apopto~le positive skeletal mr;solo 
myocyto~, ~howed a etgntflcent lower re ,  max as pts wllh npoptosis negative 
biopsies (13,5 t 4,3 vs 17.1 * 3.8 ml/kg.mln', p ,, 0.02). P53 protein ex- 
pression wa~ detected by im~'nunohistoohemistry In 17 pts (55%1 with CHF 
and in none of the control biopsies. Sorrel ,sections stained tar p53 nod for 
apapto~ts revealed thet none of the investigated nuclei wore positive for beth 
parnmetem. 
The met#Its of the pro,~ont study indtcale 1hat apoptosis is present in SM 
of mnny pts with CHF. TI~o deteclion of apoptosts soorcs to PO related to a 
lower functional oepaotty, but it, unrelated to p53 expression. 
Treatment of Shock Due to Ventrlcular 
Dysfunction 
Tuesday, March 31, 1998, Noon-2:00 p.m. 
Georgia World Congress Center, West Exhibit Hall Level 
Presentation Hour: 1:00 p,m,-2:00 p.m. 
~1 Inducible Nitric Oxide Synthase Inhibition 
Reverses Impaired Mlcrovasculer Catecholsmlne 
Reactivity In Septic Mice 
S.M. Hollenborg, C.R. Easington. J. Osrcan, J.E. ParnUo. Section at 
Cardiology, Rush Medical College, Chicago, IL, USA 
Introduchon: Pomistont vasodilntion rcfraclory to vasoprcssor catocholami- 
nee is 1he charcctonstic homodynemic abnormalily in septic shock and results 
in hypotension, hypopodusion, and a high mortality. To test the hypothesis 
that overproduction of nitric oxide by cytokine-induciblo NOS tiNeS) plays 
a pivotal rote in inducing vasculer hyporcsponsivoness in sepsis, we used 
in viva videomicrcscopy to compare tire effects of nonselective nitnc oxide 
synthaso inhibitors on norap~nephrine (NE)-inducod arteriolar constnct=on in 
septic mice. 
Methods: Mice made septic by cecal ligation and puncture were compared 
to controls that undo~,~ent sham ligation. Using image-sheanng videorci- 
cmscopy, maximal vasoconstriction in respons,~ to topically suffused NE was 
measured in crcmasteric resistance arterioles (15-20 microns) el septic and 
control mice. Reactivity was measured before and after suffusion of the 
muscle with the selective iNOS inhibitor S-methyl-isolhiourea (SMT). 
Results: The miercvasculature of septic mice was hyporesponsive com- 
pared to control mice (ECs ,, concentration that produces half-maximal con- 
striction 6.b 1 t~ M vs 0.056 ~ M, n = 5, p .. 0.05). This abnormality was partially 
reversed by sulfusion of the muscle with SMT (ECs0 0,39 t~M, n = 5, p 
0,05 vs septic). SMT had no significant effect on responses in control mice 
(ECho 6.5 I~M), 
Conclusion: Impaired m;crovas~ ,ular catecholamine responsiveness in re- 
sistance arterioles of septic mice ;n viva was partially reversed by selective 
iNOS inhibition with SMT. This s¢,ggests that nitric oxide produced by cy- 
toktno-lnduclblo NOS plays an Important role in the rofrecton/vasoditation 
and catecholemino hyporoactivlty soon in patients with septic shock, 
~ O n e  Year Outcome Af te r  "rreneplantatlon Cardiac 
Is Not Compromised by Elevated Protransplnnt 
Panel ,-.,)active Atltlbody Levels In Patients With 
Ventrleular Assist Devices 
S, Trohnn, S,H, McKollar, J, Markn, D,A, Bsll, J.C= Stttnghnm, DO, T~ylor, 
D, Ronlund, T.C. Fuller, J,W. Long, UTAHCaKtiac liansplant Program, ~e 
LakP Ct~ Utah, USA 
Dnckgro~lnd: The effect el protr~msplant panel roacftvo antttmt~e~ (PRA) o¢, 
oardiac tran~plant~,tion (CT) oBtgome is not clear, Published .mporl~ ~.tJgg~st 
n correlation between PRA ~ 10% and compromised post transplant oH~ 
with early nod fmq~¢ent rejection, The known incidence of eJewt~l PRA in 
patio.eta receiving vontncular assist devices (VAD) or mtilicial hearts (AH) 
while awaiting CT raises concern about post transplant outcome. 
Methods: All rejection episodes duflng the first year post transplant were 
reviewed for 17 patients rocoiving VAD (TCt) or AH (CardioWesB 1hess 
patioflte wore divided into two gro~qpa: grotlp I had a PRA,  10%, group II had 
n PRA , 10% Those two groups wore compared 1o a control group, group Iff, 
of randomly selected CT patients with PRA. 10% eel receiving VAD/AH All 
patients und01went CT over the same 3 year ponod. Reloclron was d¢Imed 
as ISHLT score ~ 2 which necessitated treatment. 
Resuffs (t Group I vs Group II, 'Group II ve Group III): 
Group I tPRA tO) II (PRA 10| IlIConttol 
0~11 n=G p= n~16 p ;  
RelOCtmn Eptso.dos 
Mt~m~ 1 2 1 5 O 6 r 
SD t 0 t $ 
Dl~ys to Filet EpLsodo 
Mo~ln 107 146 06 ~' 
SD t 07 r 7~ 
12 03" 
13 
6.5 or" 
61 
Conclusrons: There was no stgndicant differcnce in the number el rciecbon 
episodes or time to first episode between any of the groups. This suggests 
that elevated PRA in VAD/AH, badge-to-transplant patients is not assooated 
with increased frequency or early onset of re|action. Larger prospecbve 
cohorts mey be required to lurther substantiate these obsenratrons 
Fl122-2-~-55 Can we Justify HEROICS in the Management of 
Post Myocardial Infarction Cardlogenlc Shock? 
M I. Walto ..~. G.C Keys, J.L. Capita, MS. Norcll. On behalfof the 
HEROICS investigators, Hull Royal Infirmar): Hull, UK 
~ackground: HEROICS (How Effechve are Revasculansatton Options In Car- 
diogenic Shock) Ls a UK based mulhcontre randomlsed control teal evaluating 
the impact of aggressive rcvascutansation strategies (either PTCAJCABG or 
aortic countoq3ulsation assisted throrcbolysls) upon 30 day mortality of post 
mfamtion cardiogonic shock. We present registry data collected from 1000 
patients with a diagnosis of myocardial mlamtzon admitted consecutively 
between 06/96 and 07/97. 
Results: Shock occurred in 96 patients (9.6%) el all Ml's, with an overall 
in hospital mortality of 89.6%. The incidence el shock was significantly 
influenced by ago (..50 yrs 5.2%, -70 yrS 14.8%; P .  0.0001), sex (14.2% 
female, 9.3% male; P .  005), MI location (LBBB 19.5%, Intoner 8.4%; P .  
0.025), Previous MI (Yes 30%, No 12%: P .- 0.0001 ) and thrcrcbolysis (lysed 
75%, not lysod 16.8%; P . 0.0001). The outcome of pharmacologically 
treated shock was universally poor whom thrombolysis was not given (42/42 
deaths 100%) and remained dismal even where it was (38/48 deaths, 79%: 
P . 0.01). The influence of age upon shock prognosis (. 80 yrs mortahty 
86%, •80 yrs 100%: P - 0.05) was also clearly apparent. 
Conclusion: Shock due to ventncelar dysfunction still occurs trcquently 
and the impact of conventional therapy is negligible for the majority. In 
consequence the role el adjunctive tntorventional strategies require definition, 
and the ongoing randomised trials (HEROICS, SHOCK and TACTICS) should 
clarify its place in the management of post infarction cardiogenic shock. 
~6-~ Aggressive Myocardial Revascularlzation 
- Strategies Improve Survival Following 
Cardlogenic Shock 
M Nahlawi, A. Abdul Karim. F. Jubran. The Cleveland Clinic Foundation, 
Cleveland, Ohio, USA 
Background: Despite contercporan/pharmacologic strategies, advanced sur- 
gical techniques and the inc, eased use of mechanical hemodynamic support 
devices, cardiogenic shock is associated with extremely high mo,lality. 
